Andersons, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Andersons, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.01B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $11.26B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $14.75B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $17.33B | Feb 19, 2025 |
| FY2021 | Dec 31, 2021 | $3.78B | Feb 24, 2022 |
| FY2021 | Sep 30, 2021 | $3.00B | Feb 24, 2022 |
| FY2021 | Jun 30, 2021 | $3.24B | Feb 24, 2022 |
| FY2021 | Mar 31, 2021 | $2.59B | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $2.51B | Feb 24, 2022 |
| FY2021 | Sep 30, 2020 | $1.89B | Feb 24, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.40B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $1.63B | Feb 18, 2026 |
| FY2023 | Dec 31, 2022 | $3.04B | Feb 21, 2024 |
| FY2023 | Dec 31, 2021 | $2.21B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.48B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.34B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $898.89M | Feb 25, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.00B | Feb 26, 2018 |
| FY2017 | Sep 30, 2017 | $836.60M | Feb 26, 2018 |
| FY2017 | Jun 30, 2017 | $993.66M | Feb 26, 2018 |
| FY2017 | Mar 31, 2017 | $852.02M | Feb 26, 2018 |
| FY2017 | Dec 31, 2016 | $1.11B | Feb 26, 2018 |
| FY2017 | Sep 30, 2016 | $859.61M | Feb 26, 2018 |
| FY2017 | Jun 30, 2016 | $1.06B | Feb 26, 2018 |
| FY2017 | Mar 31, 2016 | $887.88M | Feb 26, 2018 |
| FY2016 | Dec 31, 2015 | $1.18B | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $909.09M | Mar 1, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $713.65M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $693.93M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $745.36M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $684.16M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $592.70M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $366.20M | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $138.36M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $109.14M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $160.73M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $109.66M | Feb 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.71M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $114.01M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $101.19M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $131.08M | Feb 19, 2025 |
| FY2021 | Dec 31, 2021 | $29.64M | Feb 24, 2022 |
| FY2021 | Sep 30, 2021 | $15.74M | Feb 24, 2022 |
| FY2021 | Jun 30, 2021 | $43.50M | Feb 24, 2022 |
| FY2021 | Mar 31, 2021 | $15.11M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $15.99M | Feb 24, 2022 |
| FY2021 | Sep 30, 2020 | ($1.06M) | Feb 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $1.00M | Mar 1, 2013 |
| FY2012 | Dec 31, 2011 | $800.0K | Mar 1, 2013 |
| FY2012 | Dec 31, 2010 | $1.80M | Mar 1, 2013 |
| FY2011 | Dec 31, 2009 | $1.40M | Feb 27, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $177.00M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $331.51M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $946.75M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $287.12M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($51.05M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($74.43M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $348.56M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($35.52M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $75.29M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $39.59M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.12M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $149.19M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $150.44M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $108.28M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $75.77M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $77.15M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $165.22M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $142.58M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $34.60M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $77.74M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.71B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $4.12B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $3.86B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $4.61B | Feb 19, 2025 |
| FY2022 | Dec 31, 2021 | $4.57B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $4.27B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.90B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.39B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.16B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.23B | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.42B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $2.52B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $2.34B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $3.18B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $3.26B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $3.11B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.71B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.52B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.34B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $1.44B | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.24B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.37B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $1.28B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.20B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.07B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $961.89M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $973.61M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $830.32M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $815.20M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $774.36M | Feb 26, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $127.86M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $127.86M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $127.86M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $129.34M | Feb 19, 2025 |
| FY2024 | Dec 31, 2021 | $129.34M | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | $131.54M | Feb 21, 2024 |
| FY2022 | Dec 31, 2019 | $131.19M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $1.86M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $6.02M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $63.93M | Feb 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.04B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $970.71M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $882.94M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $807.77M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $702.76M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $626.08M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $642.69M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $647.52M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $633.50M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $609.21M | Feb 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.28M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $561.77M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $643.85M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $115.27M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $216.44M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $29.12M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $54.90M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $22.59M | Feb 27, 2020 |
| FY2019 | Dec 31, 2017 | $34.92M | Feb 27, 2020 |
| FY2019 | Dec 31, 2016 | $62.63M | Feb 27, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $560.02M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $608.15M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $562.96M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $492.52M | Feb 21, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 3 | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | 3 | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | 3 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Feb 27, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 3 | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | 2 | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | 3 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Feb 27, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.85M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $26.27M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $25.37M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $24.61M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $23.75M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $23.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $22.12M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $18.64M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $18.15M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $17.36M | Feb 27, 2019 |